Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive Advanced Urothelial Cancer
NCT03809013Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by RemeGen. Started Jan 2019; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03809013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809013.